BioSpace News Archive

OncoSec President and CEO Daniel J. O’Connor Explains How Transaction Benefits Shareholders

Former World Record competition swimmer joins cannabinoid biopharmaceutical leader

Shineco, Inc. announced that its wholly owned subsidiary Tenjove NewHemp Biotech Co., Ltd. has achieved progress in its industrial product system which focuses on cannabidiol development.

CVS Pharmacy, the retail division of CVS Health, announced that it has completed the rollout of time delay safes in all of its 58 CVS Pharmacy locations in West Virginia, including pharmacies located in Target stores.

An experienced drug development executive focused on neuromuscular disease, neuroscientist Dr. Hesterlee brings a unique background in the pharma, biotech and nonprofit sectors

Study highlights lower hospitalization rates in adults 65 years and older living in U.S. nursing homes who received an adjuvanted influenza vaccine versus standard trivalent influenza vaccine

Gift is one of the largest ever to Beaumont, will support emergency medicine and future hospital needs

Independent expert panel recognizes gut and immune supporting ingredient from leading biotechnology company as Generally Recognized as Safe (GRAS)

Elliott confirms that it has had a multiyear, constructive and private engagement with Alexion that has led to value-creative changes at the Company.

Ocugen, Inc., (NASDAQ: OCGN), ), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases, today announced that it has completed 50% of enrollment of its Phase 3 clinical trial for OCU300 for patients with ocular Graft Versus Host Disease (oGVHD).